Bio News

Cerevance’s Parkinson’s Drug Succeeds in Phase 3; Company to Discuss Next Steps With FDA

U.S.-based Cerevance said its Parkinson’s disease drug candidate solenzefpras met the primary endpoint in a late-stage clinical trial. The company randomly assigned 341 participants to placebo, low-dose and high-dose groups and compared outcomes. The high-dose group’s average dai

8 days ago

MimiVax’s Glioblastoma Vaccine Misses Primary Endpoint in Phase 2 Trial, but Shows “Clinical Significance”

U.S.-based MimiVax did not meet the primary endpoint in a Phase 2 clinical trial of SurVaxM, its glioblastoma vaccine. Median overall survival was 24.2 months in the SurVaxM group, longer than the 20.2 months in the placebo group. MimiVax plans to pursue U.S. Food and Drug Admini

8 days ago

Hanmi Pharmaceutical’s Obesity Drug Efpeo Auto-Injector Approved in South Korea

Hanmi Pharmaceutical said its investigational obesity treatment Efpeo Auto-Injector (efpeglenatide) has received marketing approval from the Ministry of Food and Drug Safety (MFDS). The drug was approved in five strengths, ranging from 2 mg to 10 mg. Hanmi Pharmaceutical is prepa

8 days ago

Shin Dong-kook to Buy Additional 1.38 Million Hanmi Science Shares, Raising Stake to 71.15%

Shin Dong-kook will acquire an additional 1,382,832 shares of Hanmi Science through an over-the-counter purchase. Shin Dong-kook signed a stock purchase agreement with Korea Value-Up Private Equity Partnership and two others. The ownership stake held by Song Young-sook and specia

8 days ago

MFDS Approves South Korea’s First GLP-1 Obesity Drug, Its 45th Locally Developed New Drug

The Ministry of Food and Drug Safety (MFDS) approved Epeo Auto Injector (epeglenatide), South Korea’s 45th locally developed new drug. The injectable is used as an adjunct for chronic weight management in adults with obesity or overweight who do not have diabetes. The MFDS forme

8 days ago

Formycon expects AI to improve biosimilar development efficiency by 20%

Germany-based Formycon is introducing artificial intelligence (AI)-based digital technology into biosimilar development. Formycon is establishing FlexGlobal’s electronic trial master file solution, FlexTMF, as its central platform. Formycon’s internal assessment found that the ne

8 days ago

Oncobase’s OB-001 Increases Brain Drug Exposure by 400%, Raising Hopes of Overcoming ADC Resistance

Oncobase said preclinical research found that OB-001 increased brain exposure to osimertinib by about 400%. OB-001 inhibits two drug efflux pumps found in the blood-brain barrier and tumor cells. Oncobase plans to advance a clinical trial combining OB-001 with osimertinib while a

8 days ago

Crop nutrient levels down 50% … 5 million U.K. adults at risk of deficiency

Deep Science Ventures (DSV) said that levels of key nutrients in crops have fallen by as much as 50% since the 1960s. As the use of glucagon-like peptide-1 (GLP-1) weight-loss drugs grows and people eat less, about 5 million working-age adults in the U.K. could fall below safe le

8 days ago

Study Identifies Cancer Cells’ Survival Strategy of Halting Proliferation, Pointing to New Approach to Prevent Brain Metastasis

Researchers found that cancer cells in the early stages of brain metastasis increase expression of the MXD4 gene and temporarily stop proliferating. This “proliferation-arrested” state gives cancer cells time to adapt to oxidative stress and DNA damage in brain tissue. Researcher

8 days ago

Children of Mothers With Gestational Diabetes Face Up to 4.3 Times Higher Risk of Type 2 Diabetes

The National Institute of Health Research announced findings from a study showing that children of mothers with gestational diabetes face a higher risk of developing diabetes. The researchers followed more than 3.49 million mother-child pairs born between 2009 and 2018 for up to

8 days ago